BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34135089)

  • 1. Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans.
    Honda S; Fukami T; Hirosawa K; Tsujiguchi T; Zhang Y; Nakano M; Uehara S; Uno Y; Yamazaki H; Nakajima M
    Drug Metab Dispos; 2021 Sep; 49(9):718-728. PubMed ID: 34135089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans.
    Yoshida T; Fukami T; Kurokawa T; Gotoh S; Oda A; Nakajima M
    Eur J Pharm Sci; 2018 Jan; 111():167-176. PubMed ID: 28966098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrolase activities of cynomolgus monkey liver microsomes and recombinant CES1, CES2, and AADAC.
    Honda S; Fukami T; Tsujiguchi T; Zhang Y; Nakano M; Nakajima M
    Eur J Pharm Sci; 2021 Jun; 161():105807. PubMed ID: 33722734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases.
    Fukami T; Kariya M; Kurokawa T; Iida A; Nakajima M
    Eur J Pharm Sci; 2015 Oct; 78():47-53. PubMed ID: 26164127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strain and sex differences in drug hydrolase activities in rodent livers.
    Kisui F; Fukami T; Nakano M; Nakajima M
    Eur J Pharm Sci; 2020 Jan; 142():105143. PubMed ID: 31726091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog.
    Kurokawa T; Fukami T; Yoshida T; Nakajima M
    Drug Metab Dispos; 2016 Mar; 44(3):409-16. PubMed ID: 26718653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indiplon is hydrolyzed by arylacetamide deacetylase in human liver.
    Shimizu M; Fukami T; Ito Y; Kurokawa T; Kariya M; Nakajima M; Yokoi T
    Drug Metab Dispos; 2014 Apr; 42(4):751-8. PubMed ID: 24464802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.
    Kobayashi Y; Fukami T; Shimizu M; Nakajima M; Yokoi T
    Drug Metab Dispos; 2012 Jun; 40(6):1080-4. PubMed ID: 22446520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase.
    Shimizu M; Fukami T; Nakajima M; Yokoi T
    Drug Metab Dispos; 2014 Jul; 42(7):1103-9. PubMed ID: 24751575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug.
    Hirosawa K; Fukami T; Nakano M; Nakajima M
    Drug Metab Dispos; 2023 Aug; 51(8):1016-1023. PubMed ID: 37137721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.
    Wang J; Williams ET; Bourgea J; Wong YN; Patten CJ
    Drug Metab Dispos; 2011 Aug; 39(8):1329-33. PubMed ID: 21540359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Human Arylacetamide Deacetylase (AADAC) on Hydrolysis of Eslicarbazepine Acetate and Effects of
    Hirosawa K; Fukami T; Tashiro K; Sakai Y; Kisui F; Nakano M; Nakajima M
    Drug Metab Dispos; 2021 Apr; 49(4):322-329. PubMed ID: 33446525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase.
    Yasuda K; Watanabe K; Fukami T; Nakashima S; Ikushiro SI; Nakajima M; Sakaki T
    Drug Metab Pharmacokinet; 2021 Aug; 39():100397. PubMed ID: 34171773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse.
    Kobayashi Y; Fukami T; Nakajima A; Watanabe A; Nakajima M; Yokoi T
    Drug Metab Dispos; 2012 Apr; 40(4):671-9. PubMed ID: 22207054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1.
    Ishizuka T; Yoshigae Y; Murayama N; Izumi T
    Drug Metab Dispos; 2013 Nov; 41(11):1888-95. PubMed ID: 23946449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.
    Sakai Y; Fukami T; Nagaoka M; Hirosawa K; Ichida H; Sato R; Suzuki K; Nakano M; Nakajima M
    Life Sci; 2021 Nov; 284():119896. PubMed ID: 34450168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology.
    Nagaoka M; Sakai Y; Nakajima M; Fukami T
    Biochem Pharmacol; 2024 May; 223():116128. PubMed ID: 38492781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxylesterase in the liver and small intestine of experimental animals and human.
    Taketani M; Shii M; Ohura K; Ninomiya S; Imai T
    Life Sci; 2007 Aug; 81(11):924-32. PubMed ID: 17764701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis.
    Watanabe A; Fukami T; Nakajima M; Takamiya M; Aoki Y; Yokoi T
    Drug Metab Dispos; 2009 Jul; 37(7):1513-20. PubMed ID: 19339378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine.
    Imai T; Taketani M; Shii M; Hosokawa M; Chiba K
    Drug Metab Dispos; 2006 Oct; 34(10):1734-41. PubMed ID: 16837570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.